CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease
about
Cerebrospinal fluid biomarkers of Alzheimer’s diseaseCerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's DiseaseImpact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic CriteriaPlasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease.Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosisThe use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and researchImago Mundi, Imago AD, Imago ADNIDiagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility studyImproving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis.Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease.Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's diseaseAlpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study.CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils.Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's diseasePrecision Medicine: Clarity for the Complexity of Dementia.CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on?The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.Non-Alzheimer's disease-related memory impairment and dementia.Brain Atrophy of Secondary REM-Sleep Behavior Disorder in Neurodegenerative Disease.CSF Apo-E levels associate with cognitive decline and MRI changesWhat can biomarkers tell us about cognition in Parkinson's disease?Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.Biomarkers in biological fluids for dementia with Lewy bodies.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Alpha-Synuclein as a Biomarker for Parkinson's Disease.Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.
P2860
Q22252572-700B3BF5-19AB-4396-9C13-7B0998659E56Q26744782-F49F8E16-CDB3-4204-8FFC-0C78B8EF2E65Q26801629-C0F3BE77-DEA4-4E3D-BB96-56E7EB128D26Q26864063-B0692110-71D6-4B80-887F-4052FBF2F175Q27322563-B0C02EEA-9B52-4D33-8076-7287367174D4Q28082380-F14D8ED9-0595-495D-A1AD-AD6B5238C8E0Q28088291-9046F8F6-22B9-406D-9040-E9AA19AD14DEQ28650395-B7EC0334-025E-4FE5-A5DB-5729362B1437Q30659251-EF56F124-61CE-44B9-BEE1-4E43436F44C4Q30971403-CDCCF66E-343A-40A5-8C9D-0500C6A3920FQ34118169-55CE23C0-909B-4F7A-8C42-F8B74070A28DQ34349522-1E9C1FE7-8B96-4B47-9512-3DB5823D8924Q34714560-D85429A2-FC5F-4455-8CCF-99CA15616B63Q35083125-8F9C8410-E336-4C99-B1E1-C968A6552A2CQ35151444-8D58BC5A-E57A-4F81-8AC0-06CE48E953A3Q36139579-997B88F1-7BB6-4AA3-9063-84FCA9FF0EA5Q36169215-9A522B0C-7899-47FE-AA5A-AEBA629380A3Q36218847-741FA1F7-27B4-4E1B-9F10-1DD5106192E2Q36245278-F6AEAE51-5301-45E7-863C-933ECA8B432AQ36753680-F7E62096-943D-4D89-9CCD-0A031D556A52Q37272860-9F483E8D-CEC5-4B2D-8978-DCA2280F3270Q37414970-9A96CA61-3C29-41C8-B997-81D3A7313684Q37451440-0D359534-A284-4B9F-A2A2-429A66B5AAEFQ37503811-A5D3390F-0C6C-41EF-9705-43B0C8CEAE40Q37698016-A5A4DFE9-041E-4834-B514-BF305EFE6957Q37705204-355D2097-578E-4139-BD8F-598E40CEB3B2Q38206497-02D34C6F-FFE8-4130-A83C-57A6691456C6Q38247307-59979DBE-339C-42E3-85E8-8ADE1765F2EAQ38283550-370288BA-52CC-4E02-AF03-2AB128EF60C1Q38289739-93241E6B-3A70-4A72-9F22-CA40883BABBEQ38575114-D2A29E3C-B4D6-4A07-87FD-3D7B280358E5Q38603309-E6B802BD-3B93-4CF2-B768-AE7162CADA03Q38759482-714BE901-590B-448F-8835-809832FD60C7Q38761739-84C0A1E2-1524-4515-A308-1CAADD41DC3EQ38825497-CDB5613F-1116-4E42-92DA-A6E8433A5F4AQ38830945-035682AB-1DEB-41A7-B854-55E6C1DB9201Q38979999-B4E4E34A-0B08-4584-9DB9-4F8BFBA31AEEQ39366291-97C6A8C3-9314-43BB-B2B3-5DC189AF2BBCQ41163005-B30EA273-69EF-432C-8A80-B961B0C8A78BQ42656279-8C334B64-A94E-4638-8BF8-2B56E48299FB
P2860
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CSF α-synuclein improves diagn ...... and Aβ in Alzheimer's disease
@en
CSF α-synuclein improves diagn ...... and Aβ in Alzheimer's disease.
@nl
type
label
CSF α-synuclein improves diagn ...... and Aβ in Alzheimer's disease
@en
CSF α-synuclein improves diagn ...... and Aβ in Alzheimer's disease.
@nl
prefLabel
CSF α-synuclein improves diagn ...... and Aβ in Alzheimer's disease
@en
CSF α-synuclein improves diagn ...... and Aβ in Alzheimer's disease.
@nl
P2093
P2860
P921
P1476
CSF α-synuclein improves diagn ...... and Aβ in Alzheimer's disease
@en
P2093
Jing Zhang
Jon B Toledo
Leslie M Shaw
P2860
P2888
P304
P356
10.1007/S00401-013-1148-Z
P577
2013-06-29T00:00:00Z